WNTresearch
WNTresearch - WNT researchWNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
    • Business concept and strategies
    • market Potential
    • Interview with the founder
    • History
    • Scientific advisors
  • Pipeline
    • Foxy-5
      • Phase 1 study
      • Phase 2 study
    • Articles
    • metastases
    • WNT signaling
    • Partners
      • Allucent
      • Biovica
      • SAGA diagnostics
      • The Sage Group
    • Box-5
    • Patents
  • Investor
    • Financial reports
    • Warrants series 2021/2023
    • Share issues
      • Rights issue 2022
    • The Share
    • presentations
    • Financial calendar
  • NEWS
    • Press Releases
    • Subscribe
  • Corporate Governance
    • Nomination committee
    • General meetings
    • Management
    • Board
    • Articles of association
  • Contact
  • English
    • Swedish

Category Archives: Emission

WNTresearch   →  Blog Large Image   →  Emission
04
Apr
Date April 4, 2019
Categories Emission

The offer in brief

Link...
Read More
Author David
01
Apr
Date April 1, 2019
Categories Emission

Memorandum new issue

Link...
Read More
Author David

Search

Categories

  • Emission 2
  • Uncategorized 12
  • VD Brev 1

Recent Posts

  • Extraordinary General Meeting on Wednesday, March 10February 5, 2021
  • BioStock publishes interview with acting CEO!October 27, 2020
  • Anders Rabbe is appointed acting CEOOctober 1, 2020
  • BioStock publishes interview with CEO Peter MorsingSeptember 24, 2020
  • BioStock publishes summer interview with CEO Peter MorsingJuly 9, 2020

Archives

  • February 2021
  • October 2020
  • September 2020
  • July 2020
  • April 2020
  • October 2019
  • August 2019
  • April 2019
  • March 2019

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

Subscribe

    

Copyright © All rights reserved.